← Leaderboards
Natura Myeku
Columbia University Health Sciences
$10,531,678
Attributed
$10,531,678
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.9M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,531,678 · 5
By mechanism
RF1$5,463,828 · 2
R01$4,322,934 · 2
K01$744,916 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Alexander Sobolevsky$12,582,489
- Elisa E Konofagou$45,415,693
- Leila Saxby Ross$168,243
- Serge E Przedborski$23,881,284
- Ikjae Lee$688,905
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposPathway InteractionsSynapsesS DiseaseMulticatalytic Endopeptidase ComplexMediatingIn VivoProteolysisTau ProteinsCellsProtein DegradationTau AggregationImpairmentTauopathiesNovel TherapeuticsProteinsNeuronsReceptorPathologyUbiquitinSignal TransductionFunctional DisorderTargeted TreatmentImpaired Cognition
Grant awards (15)
Functional And Multi-Omics Approaches To Elucidate The Regulation Of Proteasome Complex In Neurodegenerative Diseases$3,145,300
RF1 · FY2025 · NS · contact PI
The Role of Immunoproteasome Function in Alzheimer's Disease and Aging$720,854
R01 · FY2025 · AG · contact PI
The Role of Immunoproteasome Function in Alzheimer's Disease and Aging$789,225
R01 · FY2024 · AG · contact PI
The Role of Synaptic Proteolysis in Alzheimer's Disease and Therapeutic Implications$563,755
R01 · FY2023 · AG · contact PI
The Role of Synaptic Proteolysis in Alzheimer's Disease and Therapeutic Implications$583,195
R01 · FY2022 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$122,241
K01 · FY2022 · AG · contact PI
The Role of Immunoproteasome Function in Alzheimer's Disease and Aging$2,318,528
RF1 · FY2021 · AG · contact PI
The Role of Synaptic Proteolysis in Alzheimer's Disease and Therapeutic Implications$557,275
R01 · FY2021 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$124,551
K01 · FY2021 · AG · contact PI
The Role of Synaptic Proteolysis in Alzheimer's Disease and Therapeutic Implications$554,035
R01 · FY2020 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$124,551
K01 · FY2020 · AG · contact PI
The Role of Synaptic Proteolysis in Alzheimer's Disease and Therapeutic Implications$554,595
R01 · FY2019 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$124,551
K01 · FY2019 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$124,511
K01 · FY2018 · AG · contact PI
Receptor-mediated clearance of synaptic tau as a novel therapy for Alzheimer's disease.$124,511
K01 · FY2017 · AG · contact PI